Log in to search using one of your social media accounts:

 

Hyper-CVAD compared to BFM-like Chemotherapy for the Treatment of Adult Acute Lymphoblastic Leukemia. A Retrospective single center analysis
Several induction regimens have been developed for adult patients with acute lymphoblastic leukemia (ALL). We demonstrate that the hyper-CVAD regimen appears to be feasible for adult patients with ALL in terms of tolerability and efficacy. Addition of TKI for Ph+ cases and rituximab for CD20+ cases were significantly more frequent in the Hyper-CVAD arm and may have affected outcomes favorably. There is still a need for large, prospective, randomized studies in order to establish the best induction regimen for adult ALL patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 20, 2016 Category: Hematology Authors: Jean El Cheikh, Imane El Dika, Radwan Massoud, Maya Charafeddine, Rami Mahfouz, Mohamed A. Kharfan-Dabaja, Ali Bazarbachi Tags: Original Study Source Type: research

A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients with Clinical or Laboratory Tumor Lysis Syndrome
Management of tumor lysis syndrome (TLS), a potentially fatal oncologic complication following initiation of chemotherapy or other cytotoxic treatment or occurring spontaneously before treatment, has significant economic impact. This retrospective study of hospital administrative data from pediatric and adult patients with laboratory or clinical TLS found that patients treated with rasburicase, compared with those receiving allopurinol, had significantly greater mean reduction in UA levels, significantly lower ICU and overall hospital length of stay, and lower total hospitalization costs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 20, 2016 Category: Hematology Authors: Mitchell S. Cairo, Stephen Thompson, Krishna Tangirala, Michael T. Eaddy Tags: Original Study Source Type: research

The Improving Survival of Patients with Hodgkin Lymphoma Over Four Decades – Experience of the British National Lymphoma Investigation (BNLI) with 6834 Patients
The management of Hodgkin lymphoma has changed markedly over the last 50 years. This is due to the expanding understanding about the biology of the disease, the development of increasingly efficacious multi-modality treatment and the recognition of how to reduce late effects. The BNLI was formed in the 1970s to co-ordinate UK research in the diagnosis and treatment of lymphoma. This paper describes the improvement in trial patient survival over four decades. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 20, 2016 Category: Hematology Authors: Amy Kwan, Nick Chadwick, Barry Hancock Tags: Original Study Source Type: research

Change in IGHV Mutational Status of CLL Suggests Origin from Multiple Clones
Current clinical CLL grading systems poorly predict overall survival and disease aggressiveness, especially in early stage patients. (1) Among the independent molecular-based CLL prognostic markers, interphase fluorescence in-situ hybridization (FISH) DNA analysis and immunoglobulin variable region heavy chain (IGHV) mutational status are the most predictive. (2, 3) There is growing evidence that compared to FISH analysis, IGHV mutational sequence status better discriminates for overall survival. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 20, 2016 Category: Hematology Authors: Afaf Osman, Christopher D. Gocke, Douglas E. Gladstone Tags: Original Study Source Type: research

The incidence and risk of cardiac events in patients with previously treated multiple myeloma vs. matched patients without multiple myeloma: an observational, retrospective, cohort study
This study provides a unique look at real world cardiac event rates for a large group of MM patients treated with selected anti-myeloma treatments. Cardiac event risk for any cardiac event including hypertensive/arterial events, cardiac dysrhythmias, CHF, IHD, cardiomyopathy, and conduction disorders was greater in MM patients with ≥3 prior drugs (n=1,723) compared to patients without MM (n=8,615). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - November 20, 2016 Category: Hematology Authors: Kristin D. Kistler, Jill Kalman, Gagan Sahni, Brian Murphy, Winifred Werther, Kanya Rajangam, Ajai Chari Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 31, 2016 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 31, 2016 Category: Hematology Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 30, 2016 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 30, 2016 Category: Hematology Source Type: research

Risk of Atrial Fibrillation and Bleeding Diathesis Associated with Ibrutinib Treatment: a Systematic Review and Pooled-Analysis of Four Randomized Controlled Trials
The goal of the present study was to precisely assess the risk of Atrial fibrillation/flutter (Afib/Aflutter) and bleeding associated with ibrutinib compared to other treatments. The risks of Afib/Aflutter and all-grade bleeding were significantly higher in the ibrutinib group. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2016 Category: Hematology Authors: Seongseok Yun, Nicole D. Vincelette, Utkarsh Acharya, Ivo Abraham Tags: Original Study Source Type: research

Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group
We reviewed 55 patients diagnosed of primary breast lymphoma, stages IE and IIE, in 16 Spanish institutions. Of the 55 cases, 96,4% correspond to non-Hodgkin lymphoma. Results on 5-year PFS and OS were 73% and 76% respectively. Current treatments achieve good control of the disease, with an OS of 5 years in 80% of the patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 16, 2016 Category: Hematology Authors: F. Franco, J. Lavernia, D. Aguiar-Bujanda, J. Miram ón, J. Gumá, R. Álvarez, J. Gómez-Codina, F. García Arroyo, M. Llanos, M. Marin Vera, J. Alfaro, C. Quero, M. Delgado, E. Nogales, F. Menarguez, M. Martinez, M. Torrente, M. Royuela, D. Abreu, M. Pr Tags: Original Study Source Type: research

Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management
Dasatinib has demonstrated durable clinical responses in patients, both as first-line and subsequent lines of therapy. Dasatinib use can result in pleural effusion in some patients, occurring any time during treatment and commonly characterized as mild to moderate in severity. Early identification of symptoms is essential in the proper management of pleural effusion. Prompt confirmation of diagnosis and management of pleural effusion can minimize morbidity and maximize the ability to preserve long-term clinical benefits with dasatinib. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 16, 2016 Category: Hematology Authors: Jorge E. Cortes, Carlos A. Jimenez, Michael J. Mauro, Alex Geyer, Javier Pinilla-Ibarz, B. Douglas Smith Tags: Review Article Source Type: research

Outcome of Adolescents and Young Adults Compared With Pediatric Patients With Acute Myeloid and Promyelocytic Leukemia
Studies on the outcome of adolescents and young adults (AYAs) with acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL) are limited. We compared outcomes of AYAs (age, 19-30 years) and pediatric (age, 0-18 years) patients with AML and APL using the Surveillance, Epidemiology, and End Results-18 registry. AYA patients with AML have worse early mortality and overall survival compared with pediatric patients with AML, whereas AYA and pediatric patients with APL have similar outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 15, 2016 Category: Hematology Authors: Syed Sameer Nasir, Smith Giri, Sara Nunnery, Mike G. Martin Tags: Original Study Source Type: research

Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders
We identified in a large database 212 patients with multiple myeloma (MM) that developed after solid organ transplantation, which is a rare form of posttransplantation lymphoproliferative disorder (PTLD-MM), and we examined overall survival and prognostic factors. PTLD-MM has a worse prognosis than MM, but improvement in survival over time outpaced that of MM over the same time period. Advanced age and elevated creatinine are associated with shorter survival. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 15, 2016 Category: Hematology Authors: Aaron S. Rosenberg, Robin Ruthazer, Jessica K. Paulus, David M. Kent, Andrew M. Evens, Andreas K. Klein Tags: Original Study Source Type: research

Predictive and Prognostic Implications of Variant Philadelphia Translocations in CML: Experience From a Tertiary Oncology Center in Southern India
Chronic myeloid leukemia with variant translocation in the imatinib era has been an area of research regarding its predictive and prognostic effect with current treatment. Our data confirm that use of imatinib overcomes the negative prognostic effect of these translocations giving similar response rates and survival outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 15, 2016 Category: Hematology Authors: Govind Babu Kanakasetty, Lakshmaiah Kuntejowdahalli, Aditi Harsh Thanky, Lokanatha Dasappa, Linu Abraham Jacob, Suresh Babu Mallekavu, Prasanna Kumari Tags: Original Study Source Type: research

Characteristics and survival outcome analysis of extramedullary involvement in adult patients with t(8;21) acute myeloid leukemia
Extramedullary involvement in acute myeloid leukemia with t(8;21) is not a rare manifestation. Extramedullary involvement has been regarded as a poor prognostic factor although t(8;21) is a favorable-risk karyotype. We analyzed 154 patients and identified extramedullary involvement was associated with young age, leukocytosis, and c-kit mutation. Outcomes were similar after transplantation-based treatment strategy regardless of extramedullary involvement. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 15, 2016 Category: Hematology Authors: Sung-Soo Park, Jae-Ho Yoon, Hee-Je Kim, Young-Woo Jeon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min Tags: Original Study Source Type: research

Survival Analyses and Prognosis of Plasma Cell Myeloma and Plasmacytoma-Like Post-Transplant Lymphoproliferative Disorders
Multiple myeloma developing after solid organ transplant represents a rare form of post-transplant lymphoproliferative disorder (PTLD-MM) that has been incompletely studied. 212 of such patients were identified in a large database and overall survival and prognostic factors examined and compared to multiple myeloma controls derived from SEER. PTLD-MM caries a worse prognosis than multiple myeloma, however improvement in survival over time has outpaced those seen in multiple myeloma over the same time period. Advanced age and elevated creatinine are associated with shortened survival. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 15, 2016 Category: Hematology Authors: Aaron S. Rosenberg, Robin Ruthazer, Jessica K. Paulus, David M. Kent, Andrew M. Evens, Andreas K. Klein Tags: Original Study Source Type: research

Acute leukemia characteristics are different around the world: the Mexican perspective
This study is the largest ever performed in Mexico regarding acute leukemia epidemiology. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 15, 2016 Category: Hematology Authors: David G ómez-Almaguer, Edson René Marcos-Ramírez, Efreen Horacio Montaño-Morales, Guillermo J. Ruiz-Argüelles, Carlos Roberto Best-Aguilera, María del Carmen López-Sánchez, Esperanza Barrera-Chairez, José Luis López-Arrollo, Christian Omar Ramos Tags: Original Study Source Type: research

Integrating genomics in myelodysplastic syndrome to predict outcomes after allogeneic hematopoietic cell transplantation
Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematopoietic neoplastic disorders most commonly occurring in the elderly population with a tendency to progress to acute leukemia. Although epigenetic therapies have improved the outcomes of MDS patients, allogeneic hematopoietic cell transplantation (HCT) remains the only curative option for these patients. Molecular characterization of MDS using next generation sequencing has expanded not only the knowledge on MDS but also the depth of understanding of evolution and contribution of recurrent somatic mutations in precursor conditions. (Source: Clinical Lym...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 15, 2016 Category: Hematology Authors: Samah Nassereddine, Taiga Nishihori, Eric Padron, Rami Mahfouz, Ali Bazarbachi, Rami S. Komrokji, Mohamed A. Kharfan-Dabaja Tags: Review Article Source Type: research

Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate
The significance of molecular response depth is not well defined in patients with chronic phase chronic myeloid leukemia (CP-CML) under imatinib treatment. We retrospectively evaluated clinical records of 178 patients with CP-CML. Eighty-eight patients achieved complete molecular response during long term follow-up. Our results implicate that deeper molecular response is associated with improvement in progression-free survival and failure-free survival. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 15, 2016 Category: Hematology Authors: I. Kaygusuz Atagunduz, T. Toptas, R. Deniz, O. Kara, A. Eser, A. Sezgin, T. Ozgumus, F. Gecgel, T. Firatli Tuglular Tags: Original Study Source Type: research

Predictive & Prognostic Implications of Variant Philadelphia Translocations in CML – Experience from a Tertiary Oncology Centre in Southern India
Chronic myeloid leukemia with variant translocation in imatinib era has been an area of research regarding its predictive and prognostic effect with current treatment. Our data confirms that use of imatinib overcomes the negative prognostic effect of these translocations giving similar response rates and survival outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 15, 2016 Category: Hematology Authors: Govind Babu Kanakasetty, Lakshmaiah Kuntejowdahalli, Aditi Harsh Thanky, Lokanatha Dasappa, Linu Abraham Jacob, Suresh Babu Mallekavu, Prasanna Kumari Tags: Original Study Source Type: research

Potential benefit of involved-field radiotherapy for patients with relapsed-refractory Hodgkin's lymphoma with incomplete response prior to autologous stem cells transplantation
We investigated the role of radiotherapy in 73 patients receiving autologous stem cell transplant (ASCT) for relapsed/refractory Hodgkin lymphoma by comparing patients who received peri-transplant RT with patients who received chemotherapy alone. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 15, 2016 Category: Hematology Authors: Mario Levis, Cristina Piva, Andrea Riccardo Filippi, Barbara Botto, Paolo Gavarotti, Patrizia Pregno, Maura Nicolosi, Roberto Freilone, Guido Parvis, Daniela Gottardi, Umberto Vitolo, Umberto Ricardi Tags: Original Study Source Type: research

A multicenter retrospective study of mogamulizumab efficacy in adult T-cell leukemia/lymphoma
Mogamulizumab recently became available for the treatment of adult T-cell leukemia/lymphoma (ATL). We conducted a multicenter retrospective study of the efficacy of mogamulizumab in ATL treatment in patients in Japan, and found that mogamulizumab is an effective therapeutic strategy in ATL. There is some concern that the use of mogamulizumab in hematopoietic stem cell transplantation patients might cause severe GVHD. Determining the optimum number of mogamulizumab administrations should be a priority for future studies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 15, 2016 Category: Hematology Authors: Satoshi Iyama, Tsutomu Sato, Hirofumi Ohnishi, Yuji Kanisawa, Shuichi Ohta, Takeshi Kondo, Akio Mori, Yutaka Tsutsumi, Hiroyuki Kuroda, Yasutaka Kakinoki, Satoshi Yamamoto, Tohru Takahashi, Motohiro Shindo, Yoshihiro Torimoto, Kazuya Sato, Hiroshi Iwasaki Tags: Original Study Source Type: research

Outcome of Adolescents and Young Adults Compared to Pediatric Patients with Acute Myeloid and Promyelocytic Leukemia
Studies on outcome of adolescents and young adults (AYAs) with acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL) are limited. We compared outcomes of AYAs (19-30 years) and pediatric (0-18 years) AML and APL patients using SEER-18 registry. AYAs with AML have worse early mortality and overall survival compared to pediatric AML, while AYAs and pediatric APL patients have similar outcomes. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 15, 2016 Category: Hematology Authors: Syed Sameer Nasir, Smith Giri, Sara Nunnery, Mike G. Martin Tags: Original Study Source Type: research

Richter's Transformation in the Era of Kinase Inhibitor Therapy: A Review
Richter's transformation (RT) is the transformation of chronic lymphocytic leukemia (CLL) into rapidly progressive B-cell lymphoma. This disease has long been recognized as a difficult-to-treat illness with poor survival outcomes. Although the incidence of RT has been well documented in previous studies, less is understood in the era of novel therapeutics, such as kinase inhibitors (KIs). The present review discusses the current risk factors, incidence, and outcomes of patients with RT in the modern era of KI therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 6, 2016 Category: Hematology Authors: Emily C. Ayers, Anthony R. Mato Tags: Review Source Type: research

Interim PET Scans in Diffuse Large B-Cell Lymphoma: Is It Ready for Prime Time?
Prognostication of patients with diffuse large B-cell lymphoma (DLBCL) has improved in the past decade with a variety of clinical, morphologic, molecular, and radiographic methods. Comparable to data on the value of interim positron emission tomography (I-PET) in Hodgkin lymphoma, several retrospective and prospective studies are attempting to assess the value of I-PET scanning in DLBCL patients. In this review, we briefly describe and analyze the various prognostic methods in DLBCL with specific focus on the value of I-PET scanning in this disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 6, 2016 Category: Hematology Authors: Maital Bolshinsky, Chadi Nabhan Tags: Review Source Type: research

Interim PET Scans in Diffuse Large B Cell Lymphoma: is it ready for prime time?
Prognostication of patients with Diffuse Large B-Cell Lymphoma (DLBCL) has improved in the past decade with a variety of clinical, morphologic, molecular, and radiographic methods. Comparable to data on the value of interim positron emission tomography (PET) in Hodgkin Lymphoma (HL), several retrospective and prospective studies are attempting to assess the value of interim-PET scanning in DLBCL patients. In this review, we briefly describe and analyze the various prognostic methods in DLBCL with specific focus on the value of interim-PET scanning in this disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 6, 2016 Category: Hematology Authors: Maital Bolshinsky, Chadi Nabhan Tags: Review Article Source Type: research

Richter ’s Transformation in the Era of Kinase Inhibitor Therapy: A Review
Richter ’s transformation (RT) is the transformation of chronic lymphocytic leukemia (CLL) into rapidly progressive b-cell lymphoma. This disease has long been recognized as a difficult-to-treat illness with poor survival outcomes. While the incidence of RT has been well documented in prior literature, le ss is understood in the era of novel therapeutics, namely, kinase inhibitors (KI). This review discusses the current risk factors, incidence, and outcomes of patients with RT in the modern era of KI therapy. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 6, 2016 Category: Hematology Authors: Emily C. Ayers, Anthony Mato Tags: Review Article Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 31, 2016 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 31, 2016 Category: Hematology Source Type: research

Impact of Routine Surveillance Imaging on Outcomes of Patients With Diffuse Large B-Cell Lymphoma After Autologous Hematopoietic Cell Transplantation
A majority (71%) of DLBCL relapses after auto-HCT are detected by routine surveillance imaging. Overall, there appears to be limited utility for routine imaging after auto-HCT except in select cases where earlier detection and salvage therapy with allogeneic HCT is a potential option. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 28, 2016 Category: Hematology Authors: Narendranath Epperla, Namrata Shah, Mehdi Hamadani, Kristin Richardson, Jonathan T. Kapke, Asmita Patel, Sravanthi P. Teegavarapu, George Carrum, Parameswaran N. Hari, Sai R. Pingali, Reem Karmali, Timothy S. Fenske Tags: Original Study Source Type: research

Impact of routine surveillance imaging on the outcomes of patients with diffuse large B-cell lymphoma following autologous hematopoietic cell transplantation
For patients with relapsed or refractory DLBCL, autologous hematopoietic cell transplantation (auto-HCT) is commonly employed. After auto-HCT, DLBCL patients are often monitored with surveillance imaging. However, there is little evidence to support this practice. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 28, 2016 Category: Hematology Authors: Narendranath Epperla, Namrata Shah, Mehdi Hamadani, Kristin Richardson, Jonathan T. Kapke, Asmita Patel, Sravanthi P. Teegavarapu, George Carrum, Parameswaran N. Hari, Sai R. Pingali, Reem Karmali, Timothy S. Fenske Tags: Original Study Source Type: research

Total Skin Electron Beam Therapy in the Treatment of Mycosis Fungoides: a review of Conventional and Low-Dose Regimens
Mycosis fungoides (MF) is the most prevalent subtype of cutaneous T-cell lymphoma, which is characterized by the proliferation of CD4+ T-cells. While often an indolent disease, most patients eventually develop progression from isolated patches to tumors and finally nodal or visceral involvement. Treatment choice is largely based on disease burden, though prognostic factors such as disease stage, patient age, and extra-cutaneous involvement must be taken into consideration. Radiation therapy represents one of the most effective therapeutic modalities in the treatment of MF. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 28, 2016 Category: Hematology Authors: Mudit Chowdhary, Arpit M. Chhabra, Shivam Kharod, Gaurav Marwaha Tags: Review Article Source Type: research

Clinical Outcome of Acute Lymphocytic Leukemia with Concurrent MLL Gene Rearrangement and t (9; 22) in the Era of Tyrosine Kinase Inhibitors
The outcome of ALL with t(9;22) (Ph+ve) have considerably improved with tyrosine kinase inhibitors (TKI) based induction chemotherapy. We sought to evaluate the outcome of ALL patients with concurrent MLL gene rearrangement (MLL) and Ph +ve in the era of TKI. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Talha Badar, Hagop Kantarjian, Jorge Cortes, Elias Jabbour, Guillermo Garcia-Manero, Susan O'Brien, Farhad Ravandi Source Type: research

Acute Tubular Necrosis Secondary to Tyrosine Kinase Inhibitor, Dasatinib, in Philadelphia Chromosome Positive ALL and a Review of the Literature
The presence of the Philadelphia chromosome in adult pre-B cell ALL (Ph+ ALL) confers a poor prognosis. Dasatinib is a second generation tyrosine kinase inhibitor (TKI) that targets the BCR-ABL1 fusion protein. It has been studied and approved in chronic phase chronic myeloid leukemia (CML) and Ph+ ALL. The medication ’s renal safety profile has been established in prospective clinical trials, as well as one large retrospective single-institution study. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Sarmen Sarkissian, Thomas Lee, Ali Amzajerdi, Richard Van Etten Source Type: research

Adoption of Pediatric-Inspired ALL Regimens by Adult Oncologists Treating Adolescents and Young Adults: A Population-Based Study
Several studies show superior outcomes for AYA ALL patients treated following pediatric, as opposed to adult, ALL regimens. Whether adult oncologists have adopted this treatment approach to AYA ALL is not currently known. We sought to provide a population based description of the landscape of AYA ALL treatment over the past decade. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Lori Muffly, Daphne Lichtensztajn, Parveen Shiraz, Theresa Keegan, Scarlett Lin-Gomez Source Type: research

Coagulopathy with Chimerism; the Risks of Rituximab
Rituximab is a chimeric monoclonal anti-CD20 antibody. It is a well-tolerated medication used in a variety of hematologic and autoimmune conditions. The most common side effects are infusion reactions and cytopenias, including thrombocytopenia. Coagulation abnormalities and fibrinolysis are quite rare and are reported only twice in the literature. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Hind Rafei, Ivan Garcia Source Type: research

MRD Detection in Egyptian ALL Patients using IGH/TCR Gene Rearrangements as Targets for Real-Time Quantitative PCR: Single Center Experience
MRD diagnostics has proven to be the strongest prognostic factor, allowing risk group assignment into different treatment arms. The MRD techniques need to be sensitive ( ≤ 10-4), applicable, fast, and affordable. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Eman Abdelsalam, Shabaan Radwaan, Hesham Abdelraheem, Taghreed Kamal Eldin, Hosny Badrawy, Mostafa Mohammed Saleh Source Type: research

Generation of a Quantitative Real Time-Polymerase Chain (Q-PCR) Assay to Identify BCR/ABL1-like ALL Cases
BCR/ABL1-like cases are characterized by a dismal outcome and a heterogeneous genomic complexity; currently, their identification is challenging. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Sabina Chiaretti, Sara Grammatico, Monica Messina, Alfonso Piciocchi, Anna Fedullo, Valentina Gianfelici, Alessia Lauretti, Grazia Fazio, Maria Martelli, Paola Fazi, Marco Vignetti, Valerio Apicella, Antonella Vitale, Cyril Salek, Gianni Cazzaniga, Anna G Source Type: research

Ponatinib Therapy for Philadelphia-Positive ALL (Ph+ ALL) Patients: Real-World Clinical Practice vs the PACE Trial
The pivotal phase 2 PACE trial (NCT01207440) evaluated ponatinib in adult patients with refractory Ph+ ALL. Prescribing data for US patients from January 2014 are available from the specialty pharmacy, Biologics, Inc. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Michael Mauro, Lisa McGarry, Mo Yang, Stephanie Lustgarten, Hui Huang Source Type: research

Updated Results from the Phase II Study of Hyper-CVAD in Combination with Ofatumumab as Frontline Therapy for Adults with CD20 Positive (CD20+) ALL
To evaluate the safety and efficacy of the combination of ofatumumab with hyper-CVAD in adults with CD20+ ALL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Ghayas Issa, Hagop Kantarjian, Farhad Ravandi, Deborah Thomas, Maria Khouri, Guillermo Garcia Manero, Rebecca Garris, Jorge Cortes, Nicholas Short, Koji Sasaki, Heather Schroeder, Tapan Kadia, Srdan Verstovsek, Naval Daver, Nitin Jain, Marina Konopleva, S Source Type: research

Complex Karyotype and Low Hypodiploidy/Near Triploidy are Adverse Prognostic Factors in Adult ALL (ALL) Independent of MRD Status
Reports on the prognostic impact of cytogenetics in adult ALL have been inconsistent. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Ghayas Issa, Hagop Kantarjian, C. Cameron Yin, Wei Qiao, Farhad Ravandi, Rita Khouri, Deborah Thomas, Nicholas Short, Koji Sasaki, Guillermo Garcia-Manero, Tapan Kadia, Jorge Cortes, Naval Daver, Gautam Borthakur, Nitin Jain, Marina Konopleva, Issa Khouri Source Type: research

High Frequency of MTHFR, MTR and TC2 Gene Polymorphisms in Guatemalan Children with ALL
Methotrexate (MTX) is a key drug in ALL (ALL) treatment; it inhibits DNA replication by blocking the conversion of 5, 10 methylene tetrahydrofolate to 5-methylene tetrahydrofolate. MTX produces neurotoxicity. The methylene tetrahydrofolatereductase (MTHFR) (C677>T and A1298>C), methionine synthase (A2756G) and TC2 transcobalamin 2 (C776G) polymorphisms are associated with the MTX neurotoxicity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Claudia Carranza, Vanessa Zamora, Mariana Herrera, Luisa Rosales, Mauricio Villegas, Mariela Guerra, Nancy Escobar, Nely Marroqu ín, Claudia Osorio, Darwin Alvarez, Luis Alvarez Source Type: research

CD47 Blockade Enhances Therapeutic Activity of TCR Mimic Antibodies to Ultra-Low Density Cancer Epitopes
T Cell Receptor mimic (TCRm) antibodies to low-density peptide epitopes from undruggable intracellular proteins presented in the context of major histocompatibility (MHC) molecules are therapeutically effective in mouse models of human cancers. CD47 blockade by use of a high affinity SIRP α variant protein (CV1) has been shown to improve the effects of monoclonal antibodies to high-density antigens in tumor models by enhancement of antibody dependent cellular phagocytosis (ADCP). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Melissa Mathias, Jonathan Sockolosky, Aaron Chang, Cheng Liu, K. Garcia, David Scheinberg Source Type: research

Clofarabine Plus Cytarabine Therapy in Fludarabine Refractory Acute Leukemia Patients
Treatment alternatives are limited for patients that are relapse after or refractory to induction regimens for acute leukemia. FLAG regimen is combination therapy with fludarabine and cytarabine has been advocated as a potentially useful salvage regimen for the treatment of relapsed or refracory acute leukemia patients. But treatment of leukemia patients refractory after FLAG salvage regimen are very diffucult and complete remission rates are very low. Cloforabine is a new nucleoside analogue with high activity against leukemic blast. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Mehmet Dogu, Ismail Sari, Sibel Hacigoglu, Ali Keskin Source Type: research

Outcome of Adult Philadelphia Chromosome-Positive ALL in a Cancer Hospital in East India
Philadelphia chromosome (Ph)-positive ALL (ALL) is the most common cytogenetic abnormality in adult ALL. We retrospectively analyzed the outcome of newly diagnosed patients with Ph-positive ALL treated at our center between May 2011 and December 2015. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Saurabh Bhave, Anupam Chakrapani, Mayur Parihar, Neeraj Arora, Deepak Mishra, Reena Nair, Mammen Chandy Source Type: research

Propensity Score Analysis: Hyper-CVAD (HCVAD) + Ponatinib vs. HCVAD + Dasatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL)
The phase II of HCVAD + ponatinib achieved excellent outcome compared to that of HCVAD + dasatinib. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Koji Sasaki, Elias Jabbour, Farhad Ravandi, Nicholas Short, Rita Khouri, Deborah Thomas, Guillermo Garcia-Manero, Naval Daver, Tapan Kadia, Marina Konopleva, Nitin Jain, Ghayas Issa, Vicki Jeanis, Gal Moore, Rebecca Garris, Naveen Pemmaraju, Jorge Cortes, Source Type: research

Frontline Therapy with Combination of Hyper-CVAD with Ponatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL): A Phase II Study
A tyrosine kinase inhibitor (TKI) with combination of intensive chemotherapy achieves high response rate in the treatment of Ph+ ALL. Ponatinib is a more potent BCR-ABL inhibitor than other TKIs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Koji Sasaki, Hagop Kantarjian, Deborah Thomas, Farhad Ravandi, Maria Khouri, Jorge Cortes, Naveen Pemmaraju, Tapan Kadia, Nicholas Short, Ghayas Issa, Rebecca Garris, Gal Moore, Vicky Jeanis, Guillermo Garcia-Manero, Gautam Borthakur, William Wierda, Susa Source Type: research

Update Results of Frontline Therapy with Combination of Hyper-CMAD with Liposomal Vincristine (M) in Patients (Pts) with ALL (ALL)
Liposomal vincristine (M=Marqibo) has been approved as a salvage chemotherapy for pts with relapsed/refractory ALL. Replacement of regular vincristine with liposomal vincristine may lead to improve outcome with reduced neurotoxicity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Koji Sasaki, Elias Jabbour, Susan O'Brien, Maria Khouri, Deborah Thomas, Guillermo Garcia-Manero, Farhad Ravandi, Gautam Borthakur, Nicholas Short, Ghayas Issa, Evguenia Gachimova, Rebecca Garris, Jorge Cortes, Hagop Kantarjian Source Type: research

Outcomes after Blinatumomab Failure in Patients with Relapsed/ Refractory (R/R) B-cell ALL (ALL)
The outcome of patients with R/R ALL post blinatumomab failure has not been thoroughly studied. Understanding the prognosis of the patients may guide clinicians to develop better treatment strategies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Musa Yilmaz, Hagop Kantarjian, Deborah Thomas, Tapan Kadia, Guillermo Garcia-Manero, Rita Khouri, Farhad Ravandi, Gautam Borthakur, Jorge Cortes, Alessandra Ferrajoli, Koji Sasaki, Jane Autry, Rebecca Garris, Kelsey Voit, Susan O ’Brien, Elias Jabbour Source Type: research